Companies in #Targeted cancer therapy

Myricx Bio is a UK-based biotech developing a pipeline of antibody-drug conjugates (ADCs) for cancer using its proprietary N-myristoyltransferase inhibitor (NMTi) payload chemistry. The company raised a GBP 90M Series A and is being acquired by Novartis for up to $1.5B.